Silence Therapeutics (SLN) Cash & Equivalents (2018 - 2026)

Silence Therapeutics (SLN) has 9 years of Cash & Equivalents data on file, last reported at $70.1 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 48.64% year-over-year to $70.1 million; the trailing twelve-month figure through Mar 2026 stood at $70.1 million (down 48.64% YoY), and the FY2025 full-year result was $11.3 million, down 90.71% from the prior year.
• Cash & Equivalents advanced to $70.1 million in Q1 2026, from $11.3 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $136.5 million in Q1 2025 to a low of $11.3 million in Q4 2025.
• A 5-year average of $76.8 million and a median of $68.6 million in 2026 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 80.93% in 2024 and tumbled 90.71% in 2025, its largest moves.
• Tracing SLN's Cash & Equivalents over 5 years: stood at $64.3 million in 2022, then increased by 4.3% to $67.1 million in 2023, then soared by 80.93% to $121.3 million in 2024, then plunged by 90.71% to $11.3 million in 2025, then surged by 521.62% to $70.1 million in 2026.
• Business Quant data shows SLN's Cash & Equivalents at $70.1 million in Q1 2026, $11.3 million in Q4 2025, and $102.2 million in Q3 2025.